BioBeats

BioBeats is a London, United Kingdom-based digital health and artificial intelligence company that develops a machine learning platform, software development kits, and mobile applications to monitor employee mental health and corporate wellness. The organization utilizes biometric data collected from connected wearable devices to deliver real-time analytics and actionable insights regarding physiological and psychological stress levels across patient populations. Prior to its strategic acquisition, the enterprise successfully secured approximately $6.5 million in venture funding from institutional backers including White Star Capital to develop and scale its flagship BioBase mobile application. In April 2020, the business was acquired by the British health technology corporation Huma, formerly known as Medopad, to integrate these digital biomarker capabilities into a broader global healthcare platform. BioBeats was officially founded in 2012 by co-founders David Plans, Nadeem Kassam, and Davide Morelli.

# BioBeats: High-Level Overview

BioBeats is a medical technology company revolutionizing hypertension diagnosis and management through FDA-cleared, cuff-less blood pressure monitoring systems.[1][2] The company develops AI-driven wearable devices that provide continuous, non-invasive, medical-grade measurements of vital signs including blood pressure, pulse rate, respiratory rate, and blood oxygen saturation.[1] BioBeats serves healthcare providers and patients globally, operating in hospitals, clinics, home care settings, and clinical research environments.[1] The company's core mission is to ensure all hypertension patients are monitored and managed effectively by empowering physicians with accurate, real-time data to optimize patient care and reduce misdiagnosis.[2][3]

The company has achieved significant commercial momentum, recently securing $50 million in Series B financing led by Ally Bridge Group, OrbiMed Advisors, and Elevage Medical.[7] This capital infusion is being deployed to expand commercialization in the United States, with the company building out a field sales team to drive adoption of its novel ambulatory blood pressure monitoring (ABPM) system.[7] BioBeats operates with offices in Tel Aviv, Israel (its headquarters at 26 Hamagshimim, Petah Tikva) and Boca Raton, Florida, positioning itself to serve both the European and North American markets.[1][7]

# Core Differentiators

• Proprietary sensor technology: BioBeats leverages patented PPG (photoplethysmography) sensor technology and advanced data analytics to deliver continuous, medical-grade monitoring without traditional blood pressure cuffs.[2]

• Regulatory clearances: The company holds FDA clearance and CE certification, enabling market access in North America and Europe.[1][2] Notably, Biobeat is the first FDA-cleared cuff-less 24-hour ambulatory blood pressure monitoring system available as a patch-worn device.[7]

• Clinical validation: The company's ABPM system is clinically validated and designed to capture critical nighttime blood pressure measurements while allowing uninterrupted patient sleep.[7]

• Comprehensive vital signs monitoring: Beyond blood pressure, the platform measures pulse rate, respiratory rate, blood oxygen saturation, and temperature, providing holistic patient data.[1]

• Diverse care settings: Solutions are deployable across hospitals, clinics, home care, and clinical research environments, maximizing addressable market.[1]

# Role in the Broader Tech Landscape

BioBeats operates at the intersection of several powerful healthcare trends: the shift toward remote patient monitoring, the digitization of chronic disease management, and the growing emphasis on continuous rather than episodic health data.[1][3] The company is riding the wave of wearable technology adoption and AI-driven clinical decision support, addressing a critical gap in hypertension management—a condition affecting over 100 million patients in the U.S. alone.[7]

The timing is particularly favorable as healthcare systems seek to reduce costs while improving outcomes, and as regulatory bodies have become more receptive to innovative monitoring technologies.[7] BioBeats' location in Israel's "Silicon Wadi" provides access to deep technical talent and research institutions, while its dual headquarters structure (Tel Aviv and Boca Raton) positions it to influence both European and North American healthcare ecosystems.[1]

# Quick Take & Future Outlook

BioBeats is well-positioned to become a standard-of-care solution for hypertension monitoring, similar to how patch-worn ambulatory ECG monitoring transformed cardiac care.[7] The company's recent $50 million Series B round signals strong investor confidence and provides the capital needed to scale commercialization aggressively. With world-class venture investors now on its board and a clear clinical value proposition, BioBeats is likely to drive broader adoption of ABPM technology and reshape how hypertension is diagnosed and managed globally.

The company's next phase will focus on converting clinical validation into widespread clinical adoption, expanding its field sales presence, and potentially extending its platform to adjacent chronic disease monitoring applications. As healthcare systems increasingly prioritize continuous monitoring and remote care delivery, BioBeats' technology addresses a fundamental need in the market.